trial

A Study for Schizophrenia Relapse Prediction

NCTId NCT03629951
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 333 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2021-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
333 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2018-11-29
Primary completion
2021-12-31
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Oral Antipsychotics (OAP)

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

10 total
Ahmedabad, IndiaAhmedabad, IndiaHyderabad, IndiaKanpur, IndiaMadurai, IndiaManipal, IndiaMumbai, IndiaNagpur, IndiaVadodara, IndiaVaranasi, India

Facts & assertions

4 sourced
Enrollment
333
Phase
NA
Primary Completion Date
2021-12-31
Status
COMPLETED
relationships
The graph out of here
drug
Oral Antipsychotics (OAP)
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication